• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从几十年前构建的人类抗体文库中筛选出的针对 SARS-CoV-2 的中和抗体。

Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.

机构信息

Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, P. R. China.

School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, P. R. China.

出版信息

Adv Sci (Weinh). 2022 Jan;9(1):e2102181. doi: 10.1002/advs.202102181. Epub 2021 Oct 29.

DOI:10.1002/advs.202102181
PMID:34716683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8646600/
Abstract

Combinatorial antibody libraries not only effectively reduce antibody discovery to a numbers game, but enable documentation of the history of antibody responses in an individual. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has prompted a wider application of this technology to meet the public health challenge of pandemic threats in the modern era. Herein, a combinatorial human antibody library constructed 20 years before the coronavirus disease 2019 (COVID-19) pandemic is used to discover three highly potent antibodies that selectively bind SARS-CoV-2 spike protein and neutralize authentic SARS-CoV-2 virus. Compared to neutralizing antibodies from COVID-19 patients with generally low somatic hypermutation (SHM), these three antibodies contain over 13-22 SHMs, many of which are involved in specific interactions in their crystal structures with SARS-CoV-2 spike receptor binding domain. The identification of these somatically mutated antibodies in a pre-pandemic library raises intriguing questions about the origin and evolution of these antibodies with respect to their reactivity with SARS-CoV-2.

摘要

组合抗体文库不仅有效地将抗体发现转化为数字游戏,而且还能够记录个体中抗体反应的历史。严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)大流行促使更广泛地应用这项技术,以应对现代大流行威胁对公共健康带来的挑战。在此,使用在 2019 年冠状病毒病(COVID-19)大流行之前构建的组合人抗体文库来发现三种高度有效的抗体,这些抗体选择性结合 SARS-CoV-2 刺突蛋白并中和真实的 SARS-CoV-2 病毒。与通常体细胞高突变(SHM)较低的 COVID-19 患者的中和抗体相比,这三种抗体含有超过 13-22 个 SHM,其中许多在与 SARS-CoV-2 刺突受体结合域的晶体结构中的特定相互作用中涉及。在大流行前的文库中鉴定出这些体细胞突变的抗体,引发了关于这些抗体与 SARS-CoV-2 反应性的起源和进化的有趣问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/8529b72a3b78/ADVS-9-2102181-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/c8ea28456d84/ADVS-9-2102181-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/5e6a193f0229/ADVS-9-2102181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/43b245d02c7f/ADVS-9-2102181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/3392a29ecfe3/ADVS-9-2102181-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/7c528825d100/ADVS-9-2102181-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/8529b72a3b78/ADVS-9-2102181-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/c8ea28456d84/ADVS-9-2102181-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/5e6a193f0229/ADVS-9-2102181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/43b245d02c7f/ADVS-9-2102181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/3392a29ecfe3/ADVS-9-2102181-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/7c528825d100/ADVS-9-2102181-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b347/8728829/8529b72a3b78/ADVS-9-2102181-g007.jpg

相似文献

1
Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.从几十年前构建的人类抗体文库中筛选出的针对 SARS-CoV-2 的中和抗体。
Adv Sci (Weinh). 2022 Jan;9(1):e2102181. doi: 10.1002/advs.202102181. Epub 2021 Oct 29.
2
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.从大规模合成噬菌体文库中快速发现多样化的中和 SARS-CoV-2 抗体。
MAbs. 2022 Jan-Dec;14(1):2002236. doi: 10.1080/19420862.2021.2002236.
3
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
4
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.鉴定针对 SARS-CoV-2 的有效人类中和抗体,对治疗和预防药物的开发具有重要意义。
Nat Commun. 2021 Aug 9;12(1):4887. doi: 10.1038/s41467-021-25153-x.
5
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.通过结合具有高效力的糖基化 RBD 构象表位来中和 SARS-CoV-2 及其关注的变异株 Alpha、Beta、Gamma 和 Delta 的鼠源单克隆抗体的分离和鉴定。
Front Immunol. 2021 Oct 26;12:750386. doi: 10.3389/fimmu.2021.750386. eCollection 2021.
6
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
7
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.SARS-CoV-2 中和性人源重组抗体,来源于大流行前健康供体,结合 RBD-ACE2 界面。
Nat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2.
8
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.SARS-CoV-2 从高中和性的 COVID-19 恢复期血浆中逃逸。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2103154118.
9
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.双对偶和多价 VH 结构域阻断 ACE2 结合并中和 SARS-CoV-2。
Nat Chem Biol. 2021 Jan;17(1):113-121. doi: 10.1038/s41589-020-00679-1. Epub 2020 Oct 20.
10
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.一组靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白多个表位的人源中和单克隆抗体。
Nat Commun. 2020 Aug 27;11(1):4303. doi: 10.1038/s41467-020-18159-4.

引用本文的文献

1
A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses.一种广泛中和抗体识别出一个独特的表位,该表位具有冠状病毒共有的特征基序。
Nat Commun. 2025 Aug 15;16(1):7580. doi: 10.1038/s41467-025-63101-1.
2
Rationally designed self-assembled peptide nanofibers provoke robust humoral immunity against nervous necrosis virus.合理设计的自组装肽纳米纤维引发针对神经坏死病毒的强大体液免疫。
J Virol. 2025 Aug 19;99(8):e0031925. doi: 10.1128/jvi.00319-25. Epub 2025 Jul 15.
3
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein.

本文引用的文献

1
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.双特异性抗体靶向刺突蛋白的不同区域,能有效中和引起关注的 SARS-CoV-2 变体。
Sci Transl Med. 2021 Oct 20;13(616):eabj5413. doi: 10.1126/scitranslmed.abj5413.
2
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.两剂 SARS-CoV-2 疫苗接种可诱导针对新出现的 SARS-CoV-2 关切变异株的强大免疫应答。
Nat Commun. 2021 Aug 17;12(1):5061. doi: 10.1038/s41467-021-25167-5.
3
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
针对 SARS-CoV-2 刺突蛋白结构位点的靶向中和抗体。
N Biotechnol. 2024 May 25;80:27-36. doi: 10.1016/j.nbt.2023.12.004. Epub 2023 Dec 20.
4
Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System.从合成免疫系统中筛选出的针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的强效靶向N端结构域(NTD)中和抗体。
Vaccines (Basel). 2023 Mar 31;11(4):771. doi: 10.3390/vaccines11040771.
5
Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants.SARS-CoV-2 刺突蛋白上的脆弱位点诱导针对具有不同抗原性的奥密克戎亚变体的广泛保护性抗体。
J Clin Invest. 2023 Apr 17;133(8):e166844. doi: 10.1172/JCI166844.
6
Effects of Prior Infection with SARS-CoV-2 on B Cell Receptor Repertoire Response during Vaccination.既往感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)对疫苗接种期间B细胞受体库反应的影响。
Vaccines (Basel). 2022 Sep 6;10(9):1477. doi: 10.3390/vaccines10091477.
7
Protective neutralizing epitopes in SARS-CoV-2.SARS-CoV-2 的保护性中和表位。
Immunol Rev. 2022 Sep;310(1):76-92. doi: 10.1111/imr.13084. Epub 2022 May 22.
8
Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与中和抗体结合预测的计算方法。
Comput Struct Biotechnol J. 2022;20:2212-2222. doi: 10.1016/j.csbj.2022.04.038. Epub 2022 May 2.
9
RT-PCR negative COVID-19.实时聚合酶链反应(RT-PCR)检测为阴性的新型冠状病毒(COVID-19)。
BMC Infect Dis. 2022 Feb 13;22(1):149. doi: 10.1186/s12879-022-07095-x.
10
Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations.基于计算机模拟的 SARS-CoV-2 刺突蛋白与人血管紧张素转化酶 2 受体和中和生物分子结合亲和力的快速评估。
Front Immunol. 2021 Nov 11;12:730099. doi: 10.3389/fimmu.2021.730099. eCollection 2021.
SARS-CoV-2 感染增强和中和抗体的体外和体内功能。
Cell. 2021 Aug 5;184(16):4203-4219.e32. doi: 10.1016/j.cell.2021.06.021. Epub 2021 Jun 18.
4
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
5
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.SARS-CoV-2 刺突缺失 H69/V70 的反复出现及其在 Alpha 变异株 B.1.1.7 中的作用。
Cell Rep. 2021 Jun 29;35(13):109292. doi: 10.1016/j.celrep.2021.109292. Epub 2021 Jun 8.
6
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.血清中和抗体及记忆 B 细胞对 SARS-CoV-2 刺突蛋白和地方性冠状病毒感染的交叉反应性。
Nat Commun. 2021 May 19;12(1):2938. doi: 10.1038/s41467-021-23074-3.
7
Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.使用竞争性噬菌体生物淘选策略分离针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体结合域的人单克隆抗体。
Antib Ther. 2020 Apr 30;3(2):95-100. doi: 10.1093/abt/tbaa008. eCollection 2020 Apr.
8
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.交叉中和抗体的联合作用可协同预防 SARS-CoV-2 和 SARS-CoV 假病毒感染。
Cell Host Microbe. 2021 May 12;29(5):806-818.e6. doi: 10.1016/j.chom.2021.04.005. Epub 2021 Apr 15.
9
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.结构基础:人源强效中和抗体对 SARS-CoV-2 感染的二价结合和抑制作用。
Cell Res. 2021 May;31(5):517-525. doi: 10.1038/s41422-021-00487-9. Epub 2021 Mar 17.
10
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.SARS-CoV-2 中和性人源重组抗体,来源于大流行前健康供体,结合 RBD-ACE2 界面。
Nat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2.